CJC-1295 Research Hub — DAC vs No-DAC GHRH Studies
CJC-1295 is a tetrasubstituted GHRH(1-29) analog studied in two forms: with a drug-affinity complex (DAC) that binds serum albumin and extends half-life to days, and without DAC (also called Mod GRF 1-29) for short, pulsatile GH stimulation.
What this hub covers
- GHRH(1-29) backbone with four stabilising substitutions
- DAC maleimide group, albumin binding and ~8-day half-life
- No-DAC variant: short half-life, pulsatile release
- Comparisons to sermorelin and tesamorelin
- Stacking research with ipamorelin and hexarelin
CJC-1295 research articles
All research →CJC-1295 DAC vs No DAC: Research Overview
A research-context comparison of CJC-1295 with and without the Drug Affinity Complex modification — pharmacokinetics, GH secretion patterns, and the implications for pulsatility.
Read article →CJC-1295 Benefits and Side Effects: A Research Guide
Published benefits, side effects, and DAC vs no-DAC comparisons for CJC-1295 — the stabilized GHRH(1-29) analog with two distinct research profiles.
Read article →Sermorelin Research Overview
Sermorelin (GHRH 1–29 NH₂) is a synthetic 29-amino acid analogue of the N-terminal active fragment of endogenous growth hormone-releasing hormone — the foundational GHRH-based research compound that established the pituitary-stimulating approach to GH axis restoration and preceded all subsequent GHRH analogues including Tesamorelin and Modified GRF 1-29.
Read article →Sermorelin Benefits and Side Effects: A Research Guide
Published benefits, side effects, and comparisons for sermorelin — the GHRH(1-29) reference peptide and closest pharmacologic proxy to physiologic GH pulses.
Read article →Tesamorelin Research Overview
A synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), studied for its role in GH/IGF-1 axis stimulation, visceral adiposity reduction, and metabolic research contexts.
Read article →Tesamorelin Benefits and Side Effects: A Research Guide
Published benefits, side effects, and comparisons for tesamorelin — the GHRH(1-44) analog with the strongest clinical evidence base for visceral-fat reduction.
Read article →Ipamorelin Research Overview
Ipamorelin: mechanism of action, receptor selectivity, GH pulse profile, and comparison to other GHRPs in research contexts.
Read article →Ipamorelin Benefits and Side Effects: A Research Guide
Published benefits, side effects, and GHRP comparisons for ipamorelin — the most receptor-selective GHRP and standard partner for GHRH analogues.
Read article →HGH vs Peptide-Based GH Stimulation: A Research Comparison
A definitive research comparison of exogenous HGH (somatropin) versus peptide-based GH axis stimulation using GHRH analogues and GHRPs — covering pulsatility, physiological authenticity, IGF-1 profiles, receptor sensitivity, regulatory status, cost, and how to select the right approach for specific research applications.
Read article →CJC-1295 research FAQ
- What is the difference between CJC-1295 DAC and no-DAC?
- The DAC (drug-affinity complex) variant adds a maleimide group that covalently binds serum albumin, extending half-life from minutes to roughly 8 days and producing sustained GH elevation. The no-DAC variant lacks this group and acts on a sermorelin-like pulsatile timescale.
- Which variant preserves GH pulsatility?
- No-DAC. Its short half-life allows endogenous GH pulses to remain discrete, which research models often prefer when studying physiological release patterns. DAC produces a more continuous elevation in GH/IGF-1.
- How does CJC-1295 compare to tesamorelin?
- Tesamorelin and CJC-1295 no-DAC are both short-acting GHRH analogues; CJC-1295 DAC is the long-acting outlier. See the CJC-1295 DAC vs No-DAC overview for a side-by-side mechanism summary.
- Why is CJC-1295 often paired with ipamorelin in research?
- GHRH analogues (CJC-1295) and GHRPs (ipamorelin) activate distinct pituitary receptors; the combination produces synergistic GH release in published models without significantly affecting cortisol or prolactin.
All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.